Hsu J, Patel SN, Wolfe JD, et al. - In this randomized clinical trial involving 52 patients [mean (SD) age was 78.4 (7) years], researchers sought to compare the short-term impact of topical dorzolamide-timolol vs placebo in eyes with neovascular age-related macular degeneration (AMD) that have persistent exudation following intravitreal anti-vascular endothelial growth factor injections. For the duration of the study, patients were randomized to use dorzolamide-timolol or artificial tears. Findings indicated that the use of dorzolamide-timolol in patients with neovascular AMD with persistent exudation resulted in improvements in anatomic but not visual acuity relative to placebo at around 3 months. It will likely take additional clinical trials with longer follow-up and larger sample sizes to establish the function, if any, of dorzolamide-timolol in neovascular AMD.